Table 1.
Characteristics of the patients according to the groups.
| Prepandemic | First wave | Interpandemic | Second wave | P-value | ||
|---|---|---|---|---|---|---|
| Number of cases | 140 | 31 | 100 | 45 | ||
| Age (years) | 51.3 ± 12.0 | 50.3 ± 11.2 | 51.2 ± 12.7 | 51.0 ± 13.3 | 0.888 | |
| Sex | Female | 138 (98%) | 31 (100%) | 98 (98%) | 44 (98%) | 0.859 |
| Male | 2 (2%) | 0 (0%) | 2 (2%) | 1 (2%) | ||
| Side of tumor | Left | 71 (50%) | 17 (55%) | 54 (54%) | 21 (47%) | 0.932 |
| Right | 69 (50%) | 14 (45%) | 46 (46%) | 24 (53%) | ||
| Symptom | Present | 95 (68%) | 28 (90%) | 76 (76%) | 29 (64%) | 0.024* |
| Absent | 45 (32%) | 3 (10%) | 24 (24%) | 16 (36%) | ||
| Type of tumor | in situ | 10 (7%) | 3 (10%) | 9 (9%) | 8 (18%) | 0.112 |
| Invasive | 130 (93%) | 28 (90%) | 91 (91%) | 37 (82%) | ||
| Primary treatment (all cases) | Surgery | 98 (70%) | 17 (55%) | 79 (79%) | 38 (84%) | 0.027* |
| NCT | 42 (30%) | 14 (45%) | 21 (21%) | 7 (16%) | ||
| Primary treatment (invasive cases) | Surgery | 88 (68%) | 14 (50%) | 70 (77%) | 38 (84%) | 0.041* |
| NCT | 42 (32%) | 14 (50%) | 21 (23%) | 7 (16%) | ||
| Surgery to breast (all cases) | BCS | 83 (60%) | 19 (61%) | 49 (52%) | 19 (50%) | 0.653 |
| Mastectomy | 56 (40%) | 12 (39%) | 46 (48%) | 19 (50%) | ||
| Surgery to breast (invasive cases) | BCS | 77 (60%) | 16 (57%) | 44 (51%) | 17 (57%) | 0.653 |
| Mastectomy | 52 (40%) | 12 (43%) | 42 (49%) | 13 (43%) | ||
| Surgery to axilla (all cases) | SLNB | 93 (68%) | 19 (70%) | 75 (80%) | 30 (77%) | 0.234 |
| ALND | 44 (32%) | 8 (30%) | 18 (20%) | 9 (23%) | ||
| Surgery to axilla (invasive cases) | SLNB | 84 (66%) | 19 (73%) | 67 (79%) | 22 (71%) | 0.234 |
| ALND | 44 (34%) | 7 (27%) | 18 (21%) | 9 (29%) | ||
| Nodal status (all cases) | Negative | 84 (60%) | 14 (45%) | 73 (73%) | 30 (67%) | 0.045* |
| Positive | 56 (40%) | 17 (55%) | 27 (27%) | 15 (33%) | ||
| Nodal status (invasive cases) | Negative | 74 (57%) | 11 (39%) | 64 (70%) | 22 (60%) | 0.049* |
| Positive | 56 (43%) | 17 (61%) | 27 (30%) | 15 (40%) | ||
| Tumor size (mm) | 24.6 ± 21.7 | 25.7 ± 20.5 | 27.0 ± 24.0 | 31.9 ± 25.7 | 0.361 | |
| T in invasive cancers | 1 | 70 (54%) | 16 (57%) | 48 (53%) | 18 (49%) | 0.646 |
| 2 | 54 (41%) | 11 (40%) | 38 (42%) | 18 (49%) | ||
| 3 | 5 (4%) | 0 (0%) | 4 (4%) | 1 (2%) | ||
| 4 | 1 (1%) | 1 (3%) | 1 (1%) | 0 (0%) | ||
| N in invasive cancers | 0 | 74 (67%) | 11 (39%) | 64 (70%) | 22 (59%) | 0.093 |
| 1 | 48 (37%) | 15 (54%) | 18 (20%) | 11 (30%) | ||
| 2 | 3 (2%) | 1 (3%) | 4 (4%) | 1 (3%) | ||
| 3 | 5 (4%) | 1 (3%) | 5 (6%) | 3 (8%) | ||
| TNM stage in invasive cancers | 1 | 54 (42%) | 8 (28%) | 38 (42%) | 14 (38%) | 0.624 |
| 2 | 65 (50%) | 17 (61%) | 40 (44%) | 18 (49%) | ||
| 3 | 11 (8%) | 3 (11%) | 13 (14%) | 5 (13%) | ||
| Biologic subtype | Luminal | 88 (68%) | 16 (57%) | 70 (77%) | 34 (92%) | 0.038* |
| Her2 | 30 (23%) | 9 (32%) | 14 (15%) | 3 (8%) | ||
| TN | 12 (9%) | 3 (11%) | 7 (8%) | 0 (0%) |
NCT, neoadjuvant chemotherapy; BCS, breast conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; Her2, Human Epidermal Growth Factor Receptor 2; TN, triple negative. *statistically significant.